【石药集团：猴痘mRNA疫苗获美国FDA临床试验批准】石药集团公告，本集团与中国科学院微生物研究所合作开发的预防用生物制品1类新药SYS6037注射液已获得美国食品药品监督管理局批准，可在美国开展临床试验。临床前研究显示，相较于减毒活疫苗，该产品具有更优的免疫原性和保护效力，且对多种正痘病毒抗原表现出广谱交叉反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.